BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment

seekingalpha04-29

BioVie (NASDAQ: BIVI) announced the grant of a clinical trial award of up to $13.1M from the U.S. Department of Defense. The award can provide up to 2 years of non-dilutive funding for a Phase 2b ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431859406?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-29 20:23","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2431859406","market":"sh","top_or_hot":-1,"title":"BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment","media":"seekingalpha","content":"<div>\n<p>BioVie (NASDAQ: BIVI) announced the grant of a clinical trial award of up to $13.1M from the U.S. Department of Defense. The award can provide up to 2 years of non-dilutive funding for a Phase 2b ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095413-biovie-awarded-up-to-131m-in-funding-from-us-dod-for-long-covid-treatment\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-29 20:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4095413-biovie-awarded-up-to-131m-in-funding-from-us-dod-for-long-covid-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioVie (NASDAQ: BIVI) announced the grant of a clinical trial award of up to $13.1M from the U.S. Department of Defense. The award can provide up to 2 years of non-dilutive funding for a Phase 2b ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095413-biovie-awarded-up-to-131m-in-funding-from-us-dod-for-long-covid-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIVI","symbol_name":"BioVie Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4095413-biovie-awarded-up-to-131m-in-funding-from-us-dod-for-long-covid-treatment","article_id":"2431859406","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431859406","pubTimestamp":1714393390,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"BioVie  announced the grant of a clinical trial award of up to $13.1M from the U.S. Department of Defense. The award can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess the Company’s anti-inflammatory and insulin sensitizer candidate, bezisterim, for the treatment of neurological symptoms that are associated with long COVID.  The company anticipates the trial to commence by early 2025. Source: Press Release","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIVI":"BioVie Inc","DOD":"Elements ETN-Dow Jones High Yiel","BK4139":"生物科技"},"translate_title":"BioVie从美国国防部获得高达1310万美元的资金用于新冠后遗症治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIVI":1,"DOD":1},"content_text":"BioVie (NASDAQ: BIVI) announced the grant of a clinical trial award of up to $13.1M from the U.S. Department of Defense. The award can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess the Company’s anti-inflammatory and insulin sensitizer candidate, bezisterim, for the treatment of neurological symptoms that are associated with long COVID.  The company anticipates the trial to commence by early 2025. Source: Press Release","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431859406"}